Browse TAL1

Summary
SymbolTAL1
NameT-cell acute lymphocytic leukemia 1
Aliases bHLHa17; TCL5; tal-1; T-cell leukemia/lymphoma protein 5; class A basic helix-loop-helix protein 17; stem ce ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00010 Helix-loop-helix DNA-binding domain
Function

Implicated in the genesis of hemopoietic malignancies. It may play an important role in hemopoietic differentiation. Serves as a positive regulator of erythroid differentiation (By similarity).

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001525 angiogenesis
GO:0001672 regulation of chromatin assembly or disassembly
GO:0001704 formation of primary germ layer
GO:0001707 mesoderm formation
GO:0002244 hematopoietic progenitor cell differentiation
GO:0002262 myeloid cell homeostasis
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0006333 chromatin assembly or disassembly
GO:0007346 regulation of mitotic cell cycle
GO:0007369 gastrulation
GO:0007498 mesoderm development
GO:0007626 locomotory behavior
GO:0010001 glial cell differentiation
GO:0019827 stem cell population maintenance
GO:0021510 spinal cord development
GO:0021515 cell differentiation in spinal cord
GO:0021516 dorsal spinal cord development
GO:0021527 spinal cord association neuron differentiation
GO:0021700 developmental maturation
GO:0021781 glial cell fate commitment
GO:0021953 central nervous system neuron differentiation
GO:0030099 myeloid cell differentiation
GO:0030218 erythrocyte differentiation
GO:0030219 megakaryocyte differentiation
GO:0030220 platelet formation
GO:0030221 basophil differentiation
GO:0030851 granulocyte differentiation
GO:0031334 positive regulation of protein complex assembly
GO:0032844 regulation of homeostatic process
GO:0032846 positive regulation of homeostatic process
GO:0034101 erythrocyte homeostasis
GO:0035162 embryonic hemopoiesis
GO:0035855 megakaryocyte development
GO:0036344 platelet morphogenesis
GO:0042063 gliogenesis
GO:0043249 erythrocyte maturation
GO:0043254 regulation of protein complex assembly
GO:0044089 positive regulation of cellular component biogenesis
GO:0045165 cell fate commitment
GO:0045637 regulation of myeloid cell differentiation
GO:0045639 positive regulation of myeloid cell differentiation
GO:0045646 regulation of erythrocyte differentiation
GO:0045648 positive regulation of erythrocyte differentiation
GO:0045787 positive regulation of cell cycle
GO:0045799 positive regulation of chromatin assembly or disassembly
GO:0045931 positive regulation of mitotic cell cycle
GO:0048332 mesoderm morphogenesis
GO:0048333 mesodermal cell differentiation
GO:0048469 cell maturation
GO:0048514 blood vessel morphogenesis
GO:0048568 embryonic organ development
GO:0048708 astrocyte differentiation
GO:0048821 erythrocyte development
GO:0048863 stem cell differentiation
GO:0048872 homeostasis of number of cells
GO:0051302 regulation of cell division
GO:0051781 positive regulation of cell division
GO:0060018 astrocyte fate commitment
GO:0060215 primitive hemopoiesis
GO:0060216 definitive hemopoiesis
GO:0060217 hemangioblast cell differentiation
GO:0060218 hematopoietic stem cell differentiation
GO:0060348 bone development
GO:0060374 mast cell differentiation
GO:0060375 regulation of mast cell differentiation
GO:0061515 myeloid cell development
GO:0098727 maintenance of cell number
GO:0098751 bone cell development
GO:1902105 regulation of leukocyte differentiation
GO:1902275 regulation of chromatin organization
GO:1903706 regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:1905269 positive regulation of chromatin organization
GO:2000036 regulation of stem cell population maintenance
Molecular Function GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding
GO:0000980 RNA polymerase II distal enhancer sequence-specific DNA binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
GO:0001085 RNA polymerase II transcription factor binding
GO:0001158 enhancer sequence-specific DNA binding
GO:0003682 chromatin binding
GO:0008134 transcription factor binding
GO:0035326 enhancer binding
GO:0042826 histone deacetylase binding
GO:0046982 protein heterodimerization activity
GO:0070888 E-box binding
Cellular Component GO:0000118 histone deacetylase complex
GO:0000785 chromatin
GO:0000790 nuclear chromatin
GO:0005667 transcription factor complex
GO:0033193 Lsd1/2 complex
GO:0044454 nuclear chromosome part
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolTAL1
NameT-cell acute lymphocytic leukemia 1
Aliases bHLHa17; TCL5; tal-1; T-cell leukemia/lymphoma protein 5; class A basic helix-loop-helix protein 17; stem ce ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TAL1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTAL1
NameT-cell acute lymphocytic leukemia 1
Aliases bHLHa17; TCL5; tal-1; T-cell leukemia/lymphoma protein 5; class A basic helix-loop-helix protein 17; stem ce ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TAL1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTAL1
NameT-cell acute lymphocytic leukemia 1
Aliases bHLHa17; TCL5; tal-1; T-cell leukemia/lymphoma protein 5; class A basic helix-loop-helix protein 17; stem ce ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TAL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2760.15
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4090.284
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1790.577
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.120.747
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.10.929
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1490.907
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2380.568
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3970.558
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.120.864
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.910.0277
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.6230.2
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2810.0749
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TAL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTAL1
NameT-cell acute lymphocytic leukemia 1
Aliases bHLHa17; TCL5; tal-1; T-cell leukemia/lymphoma protein 5; class A basic helix-loop-helix protein 17; stem ce ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TAL1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTAL1
NameT-cell acute lymphocytic leukemia 1
Aliases bHLHa17; TCL5; tal-1; T-cell leukemia/lymphoma protein 5; class A basic helix-loop-helix protein 17; stem ce ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TAL1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TAL1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTAL1
NameT-cell acute lymphocytic leukemia 1
Aliases bHLHa17; TCL5; tal-1; T-cell leukemia/lymphoma protein 5; class A basic helix-loop-helix protein 17; stem ce ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TAL1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTAL1
NameT-cell acute lymphocytic leukemia 1
Aliases bHLHa17; TCL5; tal-1; T-cell leukemia/lymphoma protein 5; class A basic helix-loop-helix protein 17; stem ce ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TAL1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTAL1
NameT-cell acute lymphocytic leukemia 1
Aliases bHLHa17; TCL5; tal-1; T-cell leukemia/lymphoma protein 5; class A basic helix-loop-helix protein 17; stem ce ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TAL1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTAL1
NameT-cell acute lymphocytic leukemia 1
Aliases bHLHa17; TCL5; tal-1; T-cell leukemia/lymphoma protein 5; class A basic helix-loop-helix protein 17; stem ce ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TAL1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.